Isatuximab Affords the R/R Multiple Myeloma Setting a Tolerable New Alternative

Rachel Narozniak, MA
Published: Tuesday, Mar 31, 2020
Ken Shain, MD, PhD

Ken Shain, MD, PhD

The recent approval of isatuximab-irfc (Sarclisa) combined with pomalidomide (Pomalyst) and dexamethasone offers adults with multiple myeloma whose disease has progressed after standard therapy a tolerable new treatment option.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication